NCT01190033

Brief Summary

This is a prospective, randomized, double-blind, placebo-controlled study. In an initial phase, 100 patients with chronic low back pain will be included in this study. The patients will be recruited through magazines and newspapers to take part in a screening for treatment of low back pain. This screening will involve the evaluation of data such as history and physical examination to classify the patient in the group of nonspecific low back pain, excluding patients with neurological alterations and the so-called Red-Flags. Procedures After the initial screening the patients will undergo diagnostic blocks of the medial branch of lumbar vertebrae L2, L3, L4 , L5 and of the first sacral vertebra (S1) with lidocaine and control with distilled water. The patients that present more than 50% of pain improvement, evaluated by the Likert scale after 30 minutes will form the study group, while the patients that do not present pain improvement with lidocaine or that present pain improvement with distilled water will be excluded. The medial branch block consists of the insertion of a 90mm, 25-gauge needle through the skin with radioscopic control up to the medial branch topography. Infusion of 1ml of 2% lidocaine should be performed in each medial branch of the abovementioned vertebrae. Control is executed in the same manner yet with infusion of 1ml of distilled water. Through the use of the diagnostic block we will have 40 patients selected for the second phase of the study. Once defined the study group should be evaluated before the procedure through the Oswestry, Roland Morris, SF-36 and VAS questionnaires. In the second phase of the study the patients will be randomized. The random division into two groups will be performed through a computerized program of random numbers. The randomization result will be kept in matt sealed envelopes to guarantee secrecy of the allocation. The neurolysis procedure will be carried out in the first group, consisting of 20 patients, and the placebo or sham procedure with the second group, also with 20 patients. The neurolysis procedure will be carried out under sterile conditions, with the patient lying prone and with the neurotome insertion sites anesthetized with 2ml of 1% lidocaine. The neurotome (Smith \& Nephew - RF) will be used for the procedure. The neurotome is a radiofrequency apparatus mounted on a 10cm electrode type 22 needle with a 5mm exposure tip. The neurotome should be introduced percutaneously in a manner similar to that adopted in the medial branch block through radioscopic control. The temperature of the electrode after its placement in the correct position is then raised to 80 °C for 90 seconds. Two neurotomies should be performed for each facet, one proximally and the other distally, due to double innervation of each facet. In the patients of the placebo group the procedure will be the same only the temperature of the neurotome will not be raised. This will be performed in a blind manner, as before starting the procedure, the surgeon will show the assistant who turns the device on or not the envelope containing the patient's group (placebo or neurotomy), yet the surgeon will not be informed whether the device has been turned on or not, having to perform the procedure in the same manner in both groups. The patients will then be reevaluated in the first month, 3 months after, 6 months after and 12 months after the procedure. The assessors will not be informed of the group to which the patient belongs, and the same scales performed in the preoperative period will be used here.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable low-back-pain

Timeline
Completed

Started Aug 2010

Longer than P75 for not_applicable low-back-pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

August 5, 2010

Completed
22 days until next milestone

First Posted

Study publicly available on registry

August 27, 2010

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

March 26, 2013

Status Verified

March 1, 2013

Enrollment Period

1.9 years

First QC Date

August 5, 2010

Last Update Submit

March 22, 2013

Conditions

Outcome Measures

Primary Outcomes (5)

  • Pain Evaluation

    Pain Scores on the Visual Analog Scale

    The Patients will be evaluated 1 week before surgery

  • Pain Evaluation

    Pain Scores on the Visual Analog Scale

    The Patients will be evaluated one month after surgery

  • Pain Evaluation

    Pain Scores on the Visual Analog Scale

    The Patients will be evaluated three months after surgery

  • Pain Evaluation

    Pain Scores on the Visual Analog Scale

    The Patients will be evaluated six months after surgery

  • Pain Evaluation

    Pain Scores on the Visual Analog Scale

    The Patients will be evaluated one year after surgery

Secondary Outcomes (11)

  • Disability evaluation

    The Patients will be evaluated one week before surgery

  • Medial Block Improvement

    one day after the medial branch block

  • Health Status

    The Patients will be evaluated one week before surgery

  • Disability evaluation

    The Patients will be evaluated one month after surgery

  • Disability evaluation

    The Patients will be evaluated three month after surgery

  • +6 more secondary outcomes

Study Arms (2)

Neurolysis

ACTIVE COMPARATOR

In this intervention the neurotome will be connected

Procedure: neurolysis

Neurotome OFF

PLACEBO COMPARATOR

neurotome not raised

Device: Neurotome OFF

Interventions

In this intervention the neurotome will be unconnected.

Neurotome OFF
neurolysisPROCEDURE

In this procedure the neurotome will be connected

Neurolysis

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • clinical diagnosis of lumbar pain in a patient with age between 20 and 60 years.
  • present clinical complaints of low back pain for 3 months or more.
  • present pain of moderate to severe intensity: visual analogue scale (VAS) \> 4.

You may not qualify if:

  • patients that develop a profile compatible with specific low back pain during treatment.
  • patients that request their withdrawal from the study at any time.
  • patients that develop an allergy to the medication used.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Orthopedics and Traumatology of the U.S.P

São Paulo, São Paulo, 05403-010, Brazil

RECRUITING

MeSH Terms

Conditions

Low Back Pain

Interventions

Nerve Block

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anesthesia, ConductionAnesthesiaAnesthesia and AnalgesiaDenervationNeurosurgical ProceduresSurgical Procedures, Operative

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD.

Study Record Dates

First Submitted

August 5, 2010

First Posted

August 27, 2010

Study Start

August 1, 2010

Primary Completion

July 1, 2012

Study Completion

July 1, 2013

Last Updated

March 26, 2013

Record last verified: 2013-03

Locations